SecBot SecBot
PRESS-RELEASE ·Filed Mar 17, 2026

CTMX

CytomX Therapeutics Inc.
NEUTRAL
Impact 6/10
Horizonweeks Processed8mo ago WireGlobeNewswire
Press release · Announcement
Actionable Insight • Neutral

Monitor for insider selling or short interest changes post-offering; assess clinical progress of Varseta-M in metastatic colorectal cancer as the key value driver. The stock may experience near-term pressure due to dilution despite the cash infusion.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$4.40
T+0 close · Mar 17, 2026 · via day close
Latest settled
−32.27%
T+60 · $2.98
Vs SPY
−43.80%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 18 $4.40entry
  2. T+1 · 8mo ago +8.64%α +8.90% · $4.78
  3. T+5 · 8mo ago −4.09%α −3.38% · $4.22
  4. T+20 · 7mo ago +11.14%α +5.09% · $4.89
  5. T+60 · 5mo ago −32.27%α −43.80% · $2.98
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CytomX Therapeutics priced a public offering of 45,990,567 shares and pre-funded warrants for 1,179,245 shares at $5.30 per share, raising $250 million in gross proceeds. The company plans to use the funds primarily for the development of its lead asset Varseta-M and other pipeline programs, with a 30-day over-allotment option for up to an additional 7,075,471 shares.

Key Financial Metrics

Deal Value
$250.0M

Key Facts

  • CytomX raised $250 million in gross proceeds through a public offering.
  • Offering includes 45,990,567 common shares and pre-funded warrants for 1,179,245 shares, priced at $5.30 per share.
  • Underwriters have a 30-day option to purchase up to an additional 7,075,471 shares.
  • Proceeds will fund development of Varseta-M (CX-2051) and other pipeline assets, plus general corporate purposes.
  • Closing expected on March 19, 2026, subject to customary conditions.

Financial Impact

$250 million gross proceeds, with potential for up to $38.5 million more if over-allotment is exercised (total ~$288.5M gross).

dilutioncashequity

Risk Factors

  • Significant shareholder dilution from issuance of nearly 47.2 million shares and warrants (pre- and post-over-allotment).
  • Forward-looking use of proceeds with no guaranteed clinical or commercial success.
  • Biotech market sensitivity to capital raises in absence of near-term catalysts.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3257862

Track record

10 reports on CTMX

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 2/10 Entry $1.98 Now $1.99 +0.25% settles Feb 8
  2. Nov 5, 202611d ago Press Release Bearish 5/10 No price data
  3. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $2.19 Now $1.99 −9.36% settles Feb 4
  4. Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $2.36 Now $1.99 −15.89% settles Jan 26
  5. Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $2.94 Now $1.99 −32.48% settles Dec 16
  6. Jun 22, 202621w ago 8-K Neutral 3/10 Entry $3.15 to $2.77 Now $1.99 −36.98% ▼ −12.22% −15.47% vs SPY
  7. Mar 17, 202634w ago Press Release Neutral 6/10 Viewing Entry $4.40 to $2.98 Now $1.99 −54.89% ▼ −32.27% −43.80% vs SPY
  8. Mar 16, 202635w ago Press Release Bearish 7/10 Entry $5.45 to $2.98 Now $1.99 +63.58% ▲ +45.32% +55.18% vs SPY
  9. Mar 16, 202635w ago Press Release Mixed 6/10 Entry $6.75 to $2.94 Now $1.99 −70.59% ▼ −56.44% −66.93% vs SPY
  10. Mar 4, 202636w ago Press Release Neutral 3/10 Entry $5.07 to $3.71 Now $1.99 −60.85% ▼ −26.82% −36.91% vs SPY
Showing 10 of 10

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 17, 2026